Adelaide Institute for Sleep Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.
Neuroscience Research Australia (NeuRA), The University of New South Wales, Sydney, New South Wales, Australia.
Respirology. 2021 Sep;26(9):878-886. doi: 10.1111/resp.14110. Epub 2021 Jun 23.
Atomoxetine combined with oxybutynin (Ato-Oxy) has recently been shown to reduce obstructive sleep apnoea (OSA) severity by >60%. However, Ato-Oxy also modestly reduced the respiratory arousal threshold, which may decrease sleep quality/efficiency. We sought to investigate the additional effect of zolpidem with Ato-Oxy on sleep efficiency (primary outcome), the arousal threshold, OSA severity, other standard polysomnography (PSG) parameters, next-day sleepiness and alertness (secondary outcomes).
Twelve participants with OSA received 10 mg zolpidem plus Ato-Oxy (80-5 mg, respectively) or Ato-Oxy plus placebo prior to overnight in-laboratory PSG according to a double-blind, randomized, crossover design (1-week washout). Participants were fitted with an epiglottic catheter, a nasal mask and pneumotachograph to quantify arousal threshold and airflow. Next-day sleepiness and alertness were assessed via the Karolinska Sleepiness Scale and a driving simulation task.
The addition of zolpidem increased sleep efficiency by 9% ± 13% (80.9% ± 16.9% vs. 88.2% ± 8.2%, p = 0.037) and the respiratory arousal threshold by 17% ± 18% (-26.6 ± 14.5 vs. -33.8 ± 20.3 cm H O, p = 0.004) versus Ato-Oxy + placebo. Zolpidem did not systematically change OSA severity. Combination therapy was well tolerated, and zolpidem did not worsen next-day sleepiness. However, median steering deviation during the driving simulator task increased following the zolpidem combination.
Zolpidem improves sleep efficiency via an increase in the respiratory arousal threshold to counteract potential wake-promoting properties of atomoxetine in OSA. These changes occur without altering the rate of respiratory events or overnight hypoxaemia. However, while the addition of zolpidem does not increase next-day perceived sleepiness, caution is warranted given the potential impact on next-morning objective alertness.
阿托西汀联合奥昔布宁(Ato-Oxy)最近被证明可使阻塞性睡眠呼吸暂停(OSA)严重程度降低>60%。然而,Ato-Oxy 也适度降低了呼吸唤醒阈值,这可能会降低睡眠质量/效率。我们旨在研究 Ato-Oxy 联合唑吡坦对睡眠效率(主要结局)、唤醒阈值、OSA 严重程度、其他标准多导睡眠图(PSG)参数、次日嗜睡和警觉度(次要结局)的额外影响。
12 名 OSA 患者按照双盲、随机、交叉设计(1 周洗脱期),分别在夜间入组前接受 10mg 唑吡坦加 Ato-Oxy(分别为 80-5mg)或 Ato-Oxy 加安慰剂治疗。患者佩戴会厌导管、鼻罩和呼吸气流仪以量化唤醒阈值和气流。次日嗜睡和警觉度通过 Karolinska 嗜睡量表和驾驶模拟任务评估。
与 Ato-Oxy+安慰剂相比,唑吡坦的加入使睡眠效率提高了 9%±13%(80.9%±16.9% vs. 88.2%±8.2%,p=0.037),呼吸唤醒阈值提高了 17%±18%(-26.6±14.5 与-33.8±20.3cmH2O,p=0.004)。唑吡坦并没有系统地改变 OSA 的严重程度。联合治疗耐受性良好,唑吡坦并没有加重次日的嗜睡。然而,在驾驶模拟器任务中,中位转向偏差在服用唑吡坦组合药物后增加。
唑吡坦通过增加呼吸唤醒阈值来提高睡眠效率,以抵消 OSA 中阿托西汀的潜在促醒作用。这些变化发生在不改变呼吸事件率或夜间低氧血症的情况下。然而,虽然唑吡坦的加入并没有增加次日的嗜睡感,但鉴于其对次日客观警觉度的潜在影响,仍需谨慎。